Sign In
Buy VTRS
$16.39
+0.120 (+0.738%)
At Close: Jul 13, 2026
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:32am, Tuesday, 19'th Dec 2023
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Vertex's stock heads for all-time high as non-opioid painkiller shows promise
12:03pm, Wednesday, 13'th Dec 2023
Vertex Pharmaceuticals Inc. shares VRTX, +10.68% were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine.
Viatris Stock Is Dirt Cheap And Worth Buying
04:34am, Friday, 24'th Nov 2023
Viatris shares had a negative 25% total return in the past 2 years, underperforming the S&P 500. The decline is likely due to the company's debt burden and stagnant revenues. Despite this, now may be
7 Low P/E Stocks Poised to Rebound
06:30am, Monday, 20'th Nov 2023
Screening for stocks with low price-to-earnings ratios is a great place to start when looking for value stocks, but your search for low P/E value stocks should not end there. That is, it's not as if y
Viatris (VTRS) Q3 Earnings Beat, Complex Generics Sales Dip
01:31pm, Wednesday, 08'th Nov 2023
Viatris (VTRS) third-quarter earnings beat estimates. While brands maintain business, the Complex generics business performs below management's expectations.
Viatris Inc. (VTRS) Q3 2023 Earnings Conference Call Transcript
09:37pm, Tuesday, 07'th Nov 2023
Viatris Inc. (NASDAQ:VTRS ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants William Szablewski - Head of Global Capital Markets Scott Smith - CEO Rajiv Malik - Presid
Viatris (VTRS) Beats Q3 Earnings Estimates
06:47pm, Tuesday, 07'th Nov 2023
Viatris (VTRS) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.86 per share a year ago.
Viatris core profit beats on generic drugs strength
06:23pm, Tuesday, 07'th Nov 2023
Viatris beat Wall Street estimates for third-quarter core profit on Tuesday, helped by strength in its generic drug portfolio, sending its shares up about 2% in extended trading.
3 Large-Cap Stocks to Buy Trading Below Book Value
01:07pm, Tuesday, 07'th Nov 2023
A recent article about bond king Bill Gross' favorite banks got me thinking about large-cap stocks trading below book value. Gross liked these three bank stocks because they sold below book value and
Should You Buy Viatris (VTRS) Ahead of Earnings?
12:02pm, Monday, 06'th Nov 2023
Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:32am, Monday, 06'th Nov 2023
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More
09:47am, Monday, 06'th Nov 2023
Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.
Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store?
12:46pm, Tuesday, 31'st Oct 2023
Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses.
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
05:05am, Tuesday, 31'st Oct 2023
Viatris tried to invalidate three of the patents covering Novo Nordisk's Ozempic. The courts rebuffed two of those attempts, but the third will be evaluated in depth.
Why Viatris (VTRS) is Poised to Beat Earnings Estimates Again
01:32pm, Monday, 30'th Oct 2023
Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
